Carisma Therapeutics Email Format
Biotechnology ResearchPennsylvania, United States11-50 Employees
Carisma Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other serious diseases. It relies on a proprietary platform that engineers macrophages and monocytes to create cell therapies that engage both innate and adaptive immune responses. Headquartered in Philadelphia, Pennsylvania, the company operates as a small to mid-sized organization pursuing programs in clinical development. The company’s cancer-focused programs include CAR-M therapies, with multiple candidates in various stages of clinical development. In May 2026, Carisma sold macrophage assets to United Immunity Co., Ltd., tied to cancer and liver fibrosis applications.